News
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, ...
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
A large, well-capitalized peer is apparently interested in a partnership deal with the company. The media outlet in question ...
Alongside her husband, Bob Duggan, Maky Zanganeh has guided cancer drug developer Summit Therapeutics to reach staggering new ...
Summit Therapeutics (NASDAQ: SMMT) has risen in prominence in the past two years thanks to a promising pipeline candidate, ivonescimab, a potential cancer treatment. It doesn't have a single drug ...
Second, SoFi could grow its revenue even without expanding its membership base, by cross-selling additional products to its ...
Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a note issued ...
Zacks Investment Research on MSN4d
Wall Street Analysts Believe Summit Therapeutics (SMMT) Could Rally 63.02%: Here's is How to TradeShares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback